Evaluation of topically administered tissue plasminogen activator for intraocular fibrinolysis in dogs

Am J Vet Res. 1994 Oct;55(10):1368-70.

Abstract

Fibrin clots were induced in eyes of dogs by injection of autogenous citrated plasma into the anterior chamber. Twenty-four hours after clot formation, one 50-microliters drop of tissue plasminogen activator at a concentration of 5 mg/ml (group 1, n = 7) was administered topically 9 times at 5-minute intervals, or a collagen shield that was hydrated with tissue plasminogen activator at a concentration of 5 mg/ml (group 2, n = 7) was applied. The contralateral eye served as a nontreated control. Serial photographs were taken of the fibrin clots after topical application of tissue plasminogen activator. Computerized morphometric analysis was then used to evaluate changes in cross-sectional surface area of the fibrin clot. There was no significant mean percentage decrease in clot surface area of treated eyes of group-1 dogs or in treated eyes of group-2 dogs. In addition, there was no significant difference in mean percentage decrease in clot surface area between treated eyes of group-1 and group-2 dogs.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Animals
  • Anterior Chamber
  • Dog Diseases / drug therapy*
  • Dogs
  • Eye Diseases / drug therapy
  • Eye Diseases / veterinary*
  • Female
  • Fibrinolysis / drug effects*
  • Male
  • Ophthalmic Solutions
  • Tissue Plasminogen Activator / administration & dosage*
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Ophthalmic Solutions
  • Tissue Plasminogen Activator